TCM
DTIL icon

Towercrest Capital Management’s Precision BioSciences DTIL Stock Holding History

Towercrest Capital Management’s Portfolio DTIL Stock Details DTIL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-5,156
Closed -$248K – 88
2022
Q2 		$248K Buy
+5,156
New +$303K 0.06% 78

Other funds holding DTIL

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CA
CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Towercrest Capital Management's DTIL Position: Q3 2022 in Review

Towercrest Capital Management sold out of Precision BioSciences (DTIL) in Q3 2022, closing a stake of 5,156 shares — an estimated $248K sold.

Towercrest Capital Management first reported a position in DTIL in Q2 2022 and held it in 1 quarter. The position peaked at $248K in Q2 2022. 102 funds tracked by Wall St. Rank hold DTIL as of Q3 2022.

  • Towercrest Capital Management reported no remaining Precision BioSciences position as of Q3 2022 after selling out during the quarter.
  • Towercrest Capital Management sold 5,156 Precision BioSciences shares in Q3 2022, an estimated $248K.
  • Towercrest Capital Management first reported a position in Precision BioSciences in Q2 2022 and held it in 1 quarter.
  • Towercrest Capital Management's Precision BioSciences position peaked at $248K in Q2 2022.
  • 102 funds tracked by Wall St. Rank held Precision BioSciences as of Q3 2022.

Based on Towercrest Capital Management's 13F filing for Q3 2022, filed 14 Nov 2022.